A proposed North American approach for genetic testing of individuals at risk for malignant hyperthermia.

Sheila Riazi, Stacey Watt, Jennifer Plester, Leslie G Biesecker

Abstract readReview

In one paragraph

Review in Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sheila RiaziMalignant Hyperthermia Investigation Unit, Department of Anesthesia and Pain Management, University Health Network, University of Toronto, Toronto, Ontario, Canada. sheila.riazi@uhn.ca.ORCID http://orcid.org/0000-0002-0670-1516

Stacey WattDepartment of Anesthesiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.

Jennifer PlesterDepartment of Anesthesiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Leslie G BieseckerCenter for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant hyperthermia, a pharmacogenetic disorder of skeletal muscle, is a potentially fatal reaction triggered by exposure to volatile anesthetics or succinylcholine. Genetic testing of the three known involved genes (RYR1, CACNA1S, and STAC3) has become the first line of testing for malignant hyperthermia susceptibility. However, genetic testing has sensitivity of only up to 70%. Contracture testing may be used to rule out the disorder for some individuals. This study outlines a stepwise approach, using clinical history and assessment as well as interpretation of genetic variants to balance risks and benefits for individuals at risk of this disorder. This work has received an Affirmation of Value designation from the American Society of Anesthesiologists (Schaumburg, Illinois) and endorsement from the Canadian Anesthesiologists' Society (Toronto, Canada).

Indexed as

Genetic TestingMalignant HyperthermiaCalcium ChannelsCalcium Channels, L-TypeGenetic Predisposition to DiseaseHumansNorth AmericaRyanodine Receptor Calcium Release ChannelSuccinylcholineCACNA1S protein, humanCalcium ChannelsCalcium Channels, L-TypeRyanodine Receptor Calcium Release ChannelRYR1 protein, humanSuccinylcholine

Identifiers

PMID42189464

DOI10.1007/s12630-026-03081-y

PMCPMC13249734

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.